blood cell count of 6,350/μL and red blood cell count of 180/μL (Table 1) . Peritoneal fluid culture was positive for Klebsiella pneumoniae; blood cultures were negative. Antibiotics were changed to meropenem 1 g IV every 12 h and amikacin 175 mg IV every 12 h. The peritoneal dialysis catheter was removed.
On the fourth day of admission, the patient developed nonblanching cyanosis, coolness, and swelling of the fingers of her right hand. The mottling was localized to the radial aspect of the right hand. Pulses were detected by color flow Doppler ultrasound, and computed tomography (CT) angiography of the upper extremity showed intact perfusion to the ulnar and radial branches of the hand (Fig. 1) . By the fifth day of admission, the radial aspect of the right hand had become increasingly discolored, and the radial artery pulse was undetectable by Doppler studies. By the seventh day of admission, her hand appeared gangrenous, with erythema ascending to the distal third of the forearm, and she underwent hand amputation on the 12th day of admission.
During the period leading up to her amputation, the patient also experienced worsening thrombocytopenia (Fig. 2) , which was complicated by hematochezia on the sixth day. Coagulation profile showed elevated prothrombin time (24.4 s; normal range 11-15 s) and activated partial thromboplastin time (70.2 s; normal range 20-35 s), a positive D-dimer assay (870 ng/ml; normal range 0-300 ng/ml), and a normal fibrinogen level (386 mg/l; normal range 200-400 mg/dl). She was given massive platelet, blood, and fresh frozen plasma transfusions, and intravenous immunoglobulin (IVIG; 400 mg/kg daily) for 5 days and plasmapheresis. Anticoagulation, which was initially managed with argatroban, was temporarily held during the episodes of hematochezia (between days 6 and 14). She was treated with multiple rounds of therapeutic plasma exchange on days 7 to 9. The lower gastrointestinal bleeding slowly resolved by day 18, and anticoagulation with argatroban was resumed. On hospital day 27, the patient complained of decreased vision in both eyes. She was noted not to be making eye contact, and she was increasingly confused. A noncontrast head CT showed a new acute to subacute infarct in the right frontal lobe extending to the right frontal operculum. Rituximab 1,000 mg was given on hospital day 34. She subsequently developed a new right hemiplegia and complete cortical blindness. Noncontrast head CT showed bilateral evolving occipital infarcts along with the right frontal lobe infarct previously noted.
The patient continued to receive anticoagulation with intravenous argatroban plus high-dose corticosteroids and received the second dose of the rituximab (1,000 mg) 15 days after the first dose. The platelet count stabilized, there was no further bleeding or thrombosis, and the patient was discharged to a subacute rehabilitation facility. Pathological discussion: right hand
The amputated hand and forearm showed extensive hemorrhagic necrosis with mottling and focal sloughing of the skin and edema and pallor of the deep subcutaneous tissue and muscle. Microscopic examination showed subcutaneous bullous edema with hemorrhagic necrosis associated with intense acute inflammation that was most intense in the subcutaneous tissues. Many arteries and veins of varying sizes showed partial or complete occlusion by fibrin thrombi (Figs. 3 and 4) , some of which were recanalized to varying degrees (Fig. 5) . Small veins and capillary beds were dilated, and the adjacent tissues showed interstitial hemorrhage. Muscle and all other tissues sampled were edematous and at least focally necrotic, but most intramuscular vessels, including capillaries (Fig. 6) , were dilated and not collapsed, although also focally occluded by fibrinous thrombi. The dilation of these vessels indicated occlusion in the venous drainage system of the affected tissues.
The pathologic findings indicated fibrinous thrombotic occlusion of all types of arteries and veins to variable degrees with variable degrees of recanalization. The findings were indicative of a widespread continuing clotting disorder of subacute onset, consistent with the vasculopathy of disseminated thrombosis seen in APS.
Clinical discussion
This APS patient presented with acute abdominal pain and hypotension due to Klebsiella peritonitis and septic shock. The hospital course was complicated by the acute infarction of the right hand, acute to subacute infarction of the right frontal lobe of the brain, and later, bilateral occipital lobes, associated with thrombocytopenia, and hematochezia.
The multi-organ involvement and rapid progression of disease raises the possibility that this patient had the accelerated variant of APS, better known as catastrophic APS (CAPS). The characteristic features of CAPS are: (a) rapid onset thrombosis (usually within 1 week) resulting in multiple-organ dysfunction syndrome (MODS), (b) pathological evidence of small-vessel thrombosis, (c) evidence of systemic inflammatory response syndrome (SIRS), and (d) high risk of unusual organ involvement [1] . Based on the international consensus of the classification criteria for CAPS, this case can be classified as "probable CAPS" with thrombocytopenia (Table 2 ) [1] . Although the thrombotic events occurred within 3 weeks (the ischemia and necrosis of the hand was noted between days 4 and 7 of hospital stay, and change in mental status reflecting frontal lobe infarct occurred on day 28), it was clear that these events (including the deep-vein thrombosis and bilateral adrenal infarcts that had occurred 2 months prior) were all part of a continuous thrombotic process. Furthermore, the rapid and diffuse small-vessel involvement that was noted on pathological analysis of the amputated hand specimen supports the diagnosis that this patient suffered a CAPS-like phenomenon rather than classic APS, which is usually limited to single venous or arterial medium-to-large vessel occlusions.
A "trigger" factor often plays an important role in the development of thrombosis in antiphospholipid antibody (aPL)-positive patients [2] . A cohort analysis of 250 patients in the international web-based CAPS registry [25] identified numerous precipitating factors for CAPS, including infection (22%), trauma (14%), anticoagulation withdrawal (7%), malignancies (7%), obstetric complications (6%), and interestingly, 40% without any identifiable triggers [3] . Given that a significant portion of CAPS patients has identifiable triggers, the accepted model of CAPS is the "double-or triple-hit hypothesis". That is, thrombosis occurs in aPL-positive patients when other nonaPL prothrombotic risk factors also exist [4, 5] . Interestingly, in addition to having aPL, hypertension, diabetes, and major infections, this patient also had a history of heparininduced thrombocytopenia (HIT). The presence of antiheparin platelet factor 4 (anti-HPF4) may represent an additional prothrombotic risk factor for APS. Alpert et al. demonstrated an association between anti-HPF4 and APS, in particular with increased incidence of arterial thrombosis, in systemic lupus erythematosus patients who are both anti-HPF4 and aPL-positive [6] .
Thrombocytopenia compounded the intravascular thrombotic complications in this patient. The patient's platelet count decreased from 145,000/μL to as low as 6/μL (Fig. 2 ) over 7 days, during which time she developed a lower gastrointestinal bleed and a necrotic right hand. The thrombocytopenia was likely a reflection of widespread thrombosis due to CAPS (platelet consumption), sepsis (with disseminated intravascular coagulation (DIC)), or both. The differential diagnosis also included an antibiotic side effect or a self-perpetuating platelet consumption process in the necrotic hand.
The prevalence of thrombocytopenia is 20% in APS and 60% in CAPS [7] ; thrombocytopenia in aPL-positive patients does not protect against thrombosis and can be associated with more severe disease and an increased risk of APS-related events. The severe thrombocytopenia in CAPS is in contrast to the milder thrombocytopenia (50,000/μL to 140,000/μL) typically seen in typical APS [7] .
Thrombosis, thrombocytopenia, coagulopathy, and hemorrhage can have multiple causes. It is often difficult to distinguish among severe sepsis, disseminated intravascular coagulation, and CAPS in a given patient [8] . Features of DIC, such as thromboembolism and bleeding, resulting in MODS can be present in about one fifth of CAPS patients [9] . Certain laboratory data may help distinguish between the two syndromes; in CAPS, the prothrombin time is not usually elevated, and fibrinogen is not decreased as they are in DIC, and persistently and significantly elevated antiphospholipid antibody (aPL) levels strongly support a CAPS-like picture [5] .
This patient experienced hematochezia on the sixth day of admission, in the setting of full anticoagulation and worsening thrombocytopenia (Fig. 2) . Anticoagulation had to be held for 9 days. Bleeding in the midst of CAPS is a disaster of the highest order; thrombotic risks increase when anticoagulation is held, as well as when fresh frozen plasma and platelets are given.
Early diagnosis and aggressive treatment with first-line therapies of anticoagulation and high-dose corticosteroids are essential in the management of CAPS. The classification Definite CAPS →All 4 criteria Probable CAPS → All 4 criteria, except for involvement of only 2 organs, systems, and/or tissues → All 4 criteria, except for the absence of laboratory confirmation at least 6 weeks apart attributable to the early death of a patient never tested for aPL before CAPS → 1, 2, and 4 → 1, 3, and 4 and the development of a third event in more than 1 week but less than 1 month, despite anticoagulation treatment a Usually, clinical evidence of vessel occlusions, confirmed by imaging techniques. Renal involvement is defined by 50% increase in serum creatinine, severe systemic hypertension (>180/ 100 mmHg), and/or proteinuria (>500 mg/24 h) b For histopathological confirmation, significant evidence of thrombosis must be present, although vasculitis may coexist occasionally c If the patient had not been previously diagnosed as having APS, the laboratory confirmation requires that presence of aPL must be detected on two or more occasions at least 6 weeks apart (not necessarily at the time of the event)
of "definite CAPS" or "probable CAPS" should play no role in the management of CAPS patients since the purpose of the "probable CAPS" definition is simply to allow initiation of treatment as soon as the CAPS diagnosis is suspected. The amputation of this patient's necrotic right hand was indicated to remove a site of refractory thrombosis and a potential source of the patient's worsening thrombocytopenia. CAPS patients have been reported to improve after the amputation of an infarcted extremity [10] . Because this patient had a history of HIT, she was treated with argatroban, a direct thrombin inhibitor, rather than heparin, although there is no published data on the use of argatroban in aPL-positive patients. This patient also required other second-line therapies for CAPS including IVIG and plasmapheresis and received the third-line agent, rituximab, because of ongoing thrombosis, severe thrombocytopenia, and a lack of clinical response to the previous interventions. Of note, there are no data demonstrating superiority of plasma exchange over IVIG, or vice versa, in the treatment of CAPS [11] . However, IVIG has been shown to effect short-term neutralization of pathological autoantibodies, as well as long-term suppression of aCL titers by inactivating idiotype-bearing B cell clones [12] . IVIG may also be beneficial for its antibacterial and antiviral effects, especially in CAPS patients who have an identifiable infectious trigger [13] . Uthman et al. compiled a review of studies that have shown the beneficial effects of plasma exchange through the removal of pathogenic IgG aCL and anti-β2-glycoprotein-I [aβ2-GPI] antibodies, complement factors, and inflammatory cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α) [14] . Rituximab has been successfully used in patients with CAPS and has resulted in rapid improvement of severe thrombocytopenia in some cases [15, 16] . However, there are only limited numbers of anecdotal reports on the use of rituximab in patients with primary, secondary, and catastrophic APS.
Immunologic discussion
Antiphospholipid syndrome is characterized by vascular thromboses and/or pregnancy morbidity with aPL (positive LA test, aCL, and/or aβ2-GPI antibodies) [17] . This family of autoantibodies is directed against plasma proteins that bind to negatively charged membrane phospholipids. Proposed mechanisms for aPL-mediated thrombosis include: (a) aPL-induced endothelial cell and monocyte activation resulting in the expression of adhesion molecules, (b) aPL-induced platelet activation by binding to phospholipid-bound annexins on the platelet membranes resulting in adhesion and thrombosis [18] , (c) aPL interferance with the protein C and S pathway and inhibition of protein C activation (thereby creating an acquired activated protein C resistance) and the tissue factor pathway inhibitor by impairing phospholipid-mediated auto-activation of factor XII [5] , and (d) aPL-induced increase in tissue factor (a physiologic trigger for coagulation) expression on monocytes [5, 19] .
The mechanism of aPL-related thrombocytopenia also remains unclear; one of the proposed mechanisms is immune-mediated antibodies against glycoprotein IIb/IIIa complex and/or glycoprotein Ib/IX [7] . Godeau et al. showed a high prevalence of platelet-specific glycoprotein antibodies (gpIIb/IIIa, gpIa/IIa, gpIbIX, gpIV, and CD9) in 73% (11/15) of APS patients with thrombocytopenia compared to only 10% (1/10) of patients in the control group (p<0.01) [20] . Antibodies other than aPL, such as specific antiplatelet glycoprotein autoantibodies, may also be responsible for the thrombocytopenia seen in APS patients, though they do not completely exclude the possibility of aPL participating in the pathogenesis of platelet dysfunction. In CAPS patients, thrombocytopenia is most likely multifactorial.
The exact pathophysiology of CAPS is also to be determined; in addition to the potential mechanisms of aPL-induced thrombosis discussed above, proposed mechanisms for CAPS suggest that thrombotic events are primarily responsible for propagating ongoing thrombosis. Similar to DIC, the initial thrombosis may act as a nidus for perpetuating further thrombosis, in a process which Kitchens has termed "thrombotic storm" during which fibrinolysis decreases via increased tissue plasminogen activator inhibitor type-1 levels [21, 22] . Progressive microthromboses occur as coagulation activation products increase in the circulation, and consumption of natural anticoagulant proteins, such as protein C, protein S, and antithrombin III, is accelerated [21] . Furthermore, massive cytokine release from an infectious etiology and/or necrotic tissues in CAPS patients contributes to SIRS, which can lead to septic shock and further disruption of the coagulation cascade.
Finally, CAPS resembles severe sepsis, with features of microvascular thrombosis, multi-organ dysfunction, and vascular dysfunction, and infection is the most common known trigger of CAPS [23] . Both CAPS and sepsis can result in SIRS, which is defined as an inflammatory reaction to injury, infection, or other stressors, and diagnosed when ≥2 or the following exist: temperature >38°C or <36°C; heart rate >90 bpm; respiratory rate >20 breaths per minute or PaCO 2 <32 mmHg; white blood cell count >12,000 cells/mm 3 , or >10% immature (band) forms [23] . In severe sepsis, there is endotoxin-induced endothelial cell injury that results in vascular dysfunction and a pro-coagulant state. Mediators involved in sepsis include TNF-α, IL-1, IL-12, IF-8, macrophage inflammatory protein, and lipid mediators such as prostaglandins and leukotrienes. Similarly, in CAPS, aPL-induced activation of endothelium results in widespread inflammation and elevated TNF-α, IL-I, and IL-6 levels [24] . Ultimately, microvascular thrombosis occurs in both CAPS and sepsis due to disturbance of coagulation and fibinolysis factors.
Conclusion
This case provides numerous important perspectives on CAPS, including both thrombotic and nonthrombotic (thrombocytopenia or bleeding) complications. Although CAPS patients suffer significant morbidity and mortality due to multiple-organ thromboses, nonthrombotic complications also factor into prognostic considerations. Further understanding of the pathogenesis of CAPS and its similarities to sepsis will aid in the development of targeted therapies to decrease the overwhelming devastating complications and mortality rate. Early recognition and aggressive treatment of CAPS is also critical to improving patient outcomes.
